Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).
作者信息
Ortega-Guillén Eduardo, Meneses Giovanni, Coila Edgar
机构信息
Hospital Nacional Alberto Sabogal Sologuren-EsSalud, Callao; Universidad Nacional Mayor de San Marcos, Lima, Peru.
Hospital San Juan de Lurigancho, Lima, Peru; Universidad Nacional Mayor de San Marcos, Lima, Peru.
出版信息
Chest. 2021 May;159(5):2110-2111. doi: 10.1016/j.chest.2020.10.088.
Abstract
摘要
相似文献
1
Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).关于伊维菌素对2019年冠状病毒病有效性的回顾性分析（ICON研究）的评论
Chest. 2021 May;159(5):2110-2111. doi: 10.1016/j.chest.2020.10.088.
2
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.阿齐霉素、利托那韦、洛匹那韦、奥司他韦、伊维菌素和肝素与 2019 年冠状病毒病和严重急性呼吸综合征冠状病毒-2 3C 样蛋白酶相互作用的分子对接。
J Nanosci Nanotechnol. 2021 Apr 1;21(4):2075-2089. doi: 10.1166/jnn.2021.19029.
3
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
4
Standard Dose Ivermectin for COVID-19.用于治疗新冠肺炎的标准剂量伊维菌素
Chest. 2021 May;159(5):2111-2112. doi: 10.1016/j.chest.2021.03.003.
5
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.连续高剂量伊维菌素对急性髓性白血病患者似乎是安全的，可为新冠病毒感染的临床药物重新利用提供依据。
Leuk Lymphoma. 2020 Oct;61(10):2536-2537. doi: 10.1080/10428194.2020.1786559. Epub 2020 Jul 1.
6
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?伊维菌素作为一种广谱宿主导向抗病毒药物：真有那么神？
Cells. 2020 Sep 15;9(9):2100. doi: 10.3390/cells9092100.
7
A five-day course of ivermectin may reduce the duration of COVID-19 illness.为期五天的伊维菌素疗程可能会缩短新冠病毒疾病的病程。
Int J Infect Dis. 2021 Sep;110:93-94. doi: 10.1016/j.ijid.2021.07.050. Epub 2021 Jul 26.
8
Ivermectin for COVID-19: Promising but not yet conclusive.用于治疗新冠肺炎的伊维菌素：有前景但尚无定论。
S Afr Med J. 2021 Jan 12;111(3):13187. doi: 10.7196/SAMJ.2021.v111i3.15522.
9
Response.
Chest. 2021 May;159(5):2112-2113. doi: 10.1016/j.chest.2020.11.017.
10
Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use.用于2019冠状病毒病的伊维菌素：临床使用前尚待充分评估。
Clin Ther. 2021 Sep;43(9):1622-1623. doi: 10.1016/j.clinthera.2021.07.007. Epub 2021 Jul 12.
本文引用的文献
1
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
2
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California.加利福尼亚州大型医疗保健系统中 COVID-19 患者的结局差异。
Health Aff (Millwood). 2020 Jul;39(7):1253-1262. doi: 10.1377/hlthaff.2020.00598. Epub 2020 May 21.
4
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.伊维菌素单独批准的剂量不是治疗 COVID-19 的理想剂量。
Clin Pharmacol Ther. 2020 Oct;108(4):762-765. doi: 10.1002/cpt.1889. Epub 2020 Jun 7.
5
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.武汉成人 COVID-19 住院患者严重程度和死亡率的危险因素。
J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.
Zotero 插件